AP NEWS

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Scope

The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Companies Featured

Aeterna Zentaris Inc. Allergan plc AstraZeneca plc Daiichi Sankyo Co. Ltd. Millendo Therapeutics Inc. Oxeia Biopharmaceuticals Inc. Pfizer Inc. RaQualia Pharma Inc. Zeria Pharmaceutical Co. Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/n7bvfq/growth_hormone?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005348/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 07:09 AM/DISC: 09/19/2018 07:08 AM

http://www.businesswire.com/news/home/20180919005348/en

AP RADIO
Update hourly